Product Description
Mechanisms of Action: VCAM-1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-002204-33 | P2 |
Completed |
Multiple Sclerosis |
2010-02-14 |
|
C32322 | P2 |
Terminated |
Multiple Sclerosis |
2009-11-01 |
|
C32325 | P2 |
Completed |
Multiple Sclerosis |
2009-03-01 |